hVIVO hails $9.2 billion Cidara takeover after key trial wins

hVIVO PLC (AIM:HVO) has praised its long-running partner Cidara Therapeutics after the American biotech agreed to be bought by MSD in a deal worth about $9.2 billion, saying the takeover highlights the value of its specialist work in early-stage drug development. The London-listed research group, which runs human challenge trials, studies in which volunteers are deliberately exposed to a virus in tightly controlled conditions, said the transaction “underscores the value of hVIVO's unique capabilities.

Proactive Investors • Nov 27, 2025

hVIVO gains validation from Cidara's takeover; broker calls it a "glowing endorsement"

Merck's agreement to acquire Cidara Therapeutics for about $9.2 billion gives hVIVO PLC (AIM:HVO) a moment of reflected glory. Peel Hunt's analysts highlight that Cidara's lead antiviral, CD388, advanced into late-stage development on the back of data generated through hVIVO's human challenge trial platform.

Proactive Investors • Nov 27, 2025

Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations

Target enrollment of 6,000 participants completed in the Northern Hemisphere Planned interim analysis in Q1 2026 will determine potential need for additional enrollment during Southern Hemisphere flu season SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it has reached target enrollment in its Phase 3 ANCHOR trial of 6,000 participants across clinical trial sites in the US and UK. The trial is designed to evaluate the safety and efficacy of CD388, a non-vaccine preventative of seasonal influenza, in populations at high-risk for complications of influenza.

GlobeNewsWire • Nov 24, 2025

SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-NUVSF, NDTAF, THS, and CDTX

NEW YORK , Nov. 21, 2025 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating NuVista Energy Ltd.

PRNewsWire • Nov 21, 2025

Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer

Bought 520,310 additional shares; position value rose by approximately $167.48 million Post-trade stake: 3,020,990 shares valued at $289.29 million CDTX is now the fund's 3rd-largest holding, accounting for approximately 19.2% of AUM

The Motley Fool • Nov 20, 2025

Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know.

Merck has announced plans to acquire Cidara Therapeutics for $9.2 billion, or $221.50 per share. Representing a heavy premium to the biotech's prior trading price, the bid caused its shares to surge.

The Motley Fool • Nov 20, 2025

Big Pharma Has Spent Nearly $150 Billion On M&A (So Far) In 2025

In this week's edition of InnovationRx, we look at the biotech deal frenzy, Recursion's incoming CEO, the infant formula botulism outbreak, and more. To get it in your inbox, subscribe here.

Forbes • Nov 19, 2025

This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover

California-based TCG Crossover Management sold 1 million shares of Cidara Therapeutics, cutting its stake by approximately $49 million in the third quarter. The transaction value equaled about 2.4% of the fund's 13F assets under management at quarter-end.

The Motley Fool • Nov 17, 2025

Merck expects over $5 billion commercial opportunity from Cidara's flu drug

Merck said on Monday it expects a non-risk adjusted commercial opportunity in excess of $5 billion from Cidara Therapeutics' experimental flu drug.

Reuters • Nov 17, 2025

Top 2 Health Care Stocks That May Fall Off A Cliff This Month

As of Nov. 17, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Benzinga • Nov 17, 2025